Head and Neck Cancers, Version 1.2015.

Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul;13(7):847-56 Authors: Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M Abstract These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages. PMID: 26150579 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Related Links:

Abstract Although salivary gland cancers comprise only ∼3-6% of head and neck cancers, treatment options for patients with advanced-stage disease are limited. Because of their rarity, salivary gland malignancies are understudied compared to other exocrine tissue cancers. The comparative lack of progress in this cancer field is particularly evident when it comes to our incomplete understanding of the key molecular signals that are causal for the development and/or progression of salivary gland cancers. Using a novel conditional transgenic mouse (K5:RANKL), we demonstrate that Receptor Activator of NFkB Ligand (...
Source: Cytokine - Category: Molecular Biology Authors: Tags: Cytokine Source Type: research
Conclusions: TLG on restaging FDG-PET predicted PFS and OS in patients with RSGC; patients with predicted poor outcome may benefit from alternate, escalated treatment strategies. Multivariate analysis of clinicopathological and imaging parametersParameterPFS HR (95.0% CI)PFS p-valueOS HR (95.0% CI)OS p-valueHistologic subtype, Adenocarcinoma vs. Non-adenocarcinoma2.27 (1.33- 3.89)0.0031.60 (0.91-2.80)0.09TMTV1.01 (0.99-1.012)0.081.00 (1.00-1.011)0.14TLG1.00 (1.00-1.001)
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Head and Neck Posters Source Type: research
Conclusion Most head and neck pathologies show a broad cellular heterogeneity making it difficult to achieve an accurate diagnosis and efficient treatment (Graf and Zavodszky, 2017; Lo Nigro et al., 2017). Single cell analysis of circadian omics (Lande-Diner et al., 2015; Abraham et al., 2018), may be a crucial tool needed in the future to fully understand the circadian control of head and neck diseases. It becomes more obvious that there is only a small genetic component but a largely unknown epigenetics and/or environmental component for most of the head and neck pathologies (Moosavi and Motevalizadeh Ardekani, 2016; He...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: July–August 2018Source: Reports of Practical Oncology &Radiotherapy, Volume 23, Issue 4Author(s): Mateusz Szewczyk, Paweł Golusiński, Jakub Pazdrowski, Piotr Pieńkowski, Sławomir Marszałek, Jacek Sygut, Wojciech GolusińskiAbstractAimThe purpose of the study was to publish our experience of salivary gland cancer treatment with large number of patients treated at a single institution.BackgroundSalivary gland cancers are rare tumors of the head and neck representing about 5% of cancers in that region and about 0.5% of all malignancies. Due to the rarity of the disease, most of the studies reg...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
The androgen receptor (AR) is a nuclear steroid receptor that binds to testosterone and dihydrotestosterone and regulates the transcription of genes leading to cell growth, differentiation and survival. AR serves as an important oncogenic signal in prostate cancers and apocrine breast cancers. Salivary duct carcinoma (SDC) is a rare subtype of head and neck cancer that is defined by an apocrine phenotype, with AR positivity by immunohistochemistry (IHC) in up to 98% of cases [1]. A recent clinical trial with leuprorelin acetate and bicalutamide has shown promising activity with an overall response rate of 42% in AR-positiv...
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Letter to the editor Source Type: research
Conclusions This report shows a single institution results of oncological treatment in patients with malignant salivary gland tumors, where positive surgical margins strongly correlate with patients’ worse outcome. Whether to extend the procedure, which very often requires sacrificing the nerve is still a question of debate.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Head&Neck, EarlyView.
Source: Head and Neck - Category: ENT & OMF Authors: Source Type: research
The major salivary glands occur in three pairs (the parotid, submandibular, and the sublingual glands), while the minor salivary glands occur as several hundred structures scattered within the mucous membranes of the mouth, oropharynx, larynx, nose, and the paranasal sinuses. In France, the cancers of the major salivary glands are rare, with an estimated incidence of 0.7/100,000 person-years in men and 0.5/100,000 person-years in women [1], and account for 1.9% and 8.6% of head and neck cancers (HNC) in men and in women, respectively [2].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionAlthough the objective responses to eribulin were uncommon, disease control was observed in the majority of patients.
Source: Head and Neck - Category: ENT & OMF Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Salivary gland cancer is an aggressive and painful cancer, but a rare tumor type accounting for only ~0.5% of cancer cases. Tumors of the salivary gland exhibit heterogeneous histologic and genetic features and they are subdivided into different subtypes, with adenoid cystic carcinomas (ACC) being one of the most abundant. Treatment of ACC patients is afflicted by high recurrence rates, the high potential of the tumors to metastasize, as well as the poor response of ACC to chemotherapy. A prerequisite for the development of targeted therapies is insightful genetic information for driver core cancer pathways. Here,...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Radiation Therapy | Salivary Gland Cancer | Toxicology